Form 4 for QNCX Quince Therapeutics, Inc.
Accepted 2025-12-29 00:00:00 ET · period of report 2024-10-23 · accession 0000912282-25-001468 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-29 | 2024-10-23 | QNCX | Benatti Luca | Dir | J - Other | — | +8,918 | 89.2K | +11% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-10-23 | J | A | 8,918 | — | 89,179 | D | — | — | (F1) In connection with the Stock Purchase Agreement between the Issuer and EryDel Italy Inc.announced in the Issuer's 8-k filed with the Securities and Exchange Commission on July 24, 2023 (the "Acquisition"), 10% of the shares of common stock of the Issuer issued to the Reporting Person in connection with the Acquisition were held back for one (1) year following closing and released to the Reporting Person on October 23, 2024. |